In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Patients with cancer want information and advice early in the disease course about how to deal with the financial stressors ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain ...

We are hopeful this positive duration of response continues and, as seen in first line non-small cell lung cancer in the ...

The 3-year overall survival rate was 82.6% in patients randomized to pembrolizumab compared to 74.8% in ... which also ...

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain ...

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...